TyG index and insulin resistance in beta-thalassemia by Jamshir, M. et al.
Int J Diabetes Dev Ctries (December 2015) 35 (Suppl 3):S529–S534 
DOI 10.1007/s13410-015-0418-9 
ORIGINAL ARTICLE
TyG index and insulin resistance in beta-thalassemia 
Mohsen Jamshir1 & Mohammad Fayaz2 & Narges Mirbehbahani3 & S. Mehran Hosseini4 
Received: 18 February 2015 /Accepted: 18 June 2015 /Published online: 30 June 2015 
# Research Society for Study of Diabetes in India 2015 
Abstract Insulin resistance (IR) underlies some glucose me­
tabolism abnormalities in thalassemia major. Recently, triglyc­
eride glucose index (TyG) has been proposed for evaluating 
insulin resistance as a simple, low cost, and accessible tool. In 
this study, the TyG index were studied for IR monitoring in 
beta-thalassemia major (βTM) patients. The participants were 
90 βTM patients on chronic regular transfusion therapy. The 
TyG index was computed based on fasting plasma glucose 
(FPG) and triglyceride (TG). The time gap between the first 
and the second TyG index survey (TyG.1 and TyG.2) was 
2 years. The agreement between TyG and HOMA-IR were 
studied with the extension of limit of agreement (LOA). We 
included 90 patients 53.3 % men (n=48).  Among  them,  
14.4 % (14.6 % male, 14.3 % female) had impaired fasting 
glucose level (e.g., 100–125 mg/dl) at first test. It rose to 
37.8 % (27.1 % male, 50 % female) during 2 years. Based 
on TyG.1, the 34.4 % of patients was detected as IR cases. 
After 2 years, the percent of IR based on TyG.2 was 82.2 %. 
The mean differences between TyG.1 and TyG.2 and their 
differences from the considered cutoff values were significant 
(P<0.001). The prediction limits between TyG and HOMA­
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IR had good agreement. These data may suggest the use of 
TyG index for detection/monitoring of IR in βTM patients. 
Keywords Insulin resistance . Beta-thalassemia major 
(βTM) . Triglyceride glucose (TyG) index 
Introduction 
Diabetes mellitus is an important and a prevalent endocrine 
complication in beta-thalassemia major patients [βTM] [1]. 
Insulin resistance (IR) is known as a causative or predisposing 
factor for development of diabetes mellitus and as an indepen­
dent cardiovascular risk factor [2–4]. The IR as a long lasting 
subclinical state can also be detected in other disorders, and its 
early detection is generally recommended. Both the improved 
life expectancy and the high prevalence of diabetes mellitus in 
secondary hemosiderosis highlight IR screening in βTM [5, 
6]. 
Different methods have been introduced for IR assessment. 
The gold standard method is euglycemic clamp, but it is inva­
sive, requires expert staff, and has very limited clinical indi­
cations. Thus, other alternative non-invasive indirect indices 
for IR risk assessment are introduced. The homeostasis model 
assessment of insulin resistance (HOMA) and the quantitative 
insulin sensitivity check index (QUICKI) are among the more 
commonly used IR surrogate. The HOMA and QUICKI index 
calculations are based on fasting plasma glucose and insulin 
level [7]. A recently introduced IR indicator is the triglyceride 
glucose (TyG) index which shows good correlations with 
euglycemic clamp, and unlike the HOMA index, its calcula­
tion is based on fasting plasma glucose (FPG) and triglyceride 
[8–14]. TyG index is initially reported for estimation of IR in 
healthy subjects. But this simple, low cost, and accessible 
index is also used for patients in a different clinical setting 
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[15, 16]. Base on our limited knowledge, there is not any data 
regarding the application of TyG index for screening IR in 
βTM. Therefore, the TyG index values and its changes over 
time were taken into attention in these patients. 
Materials and methods 
Setting and eligibility criteria 
This observational longitudinal study started in 2012 with 
more than 200 cases according to the considered criteria in­
cluding: negative drug history for exogenous insulin and other 
anti-diabetic agents, no history of diagnosed diabetes at the 
beginning of study, negative drug and clinical history of hy­
perlipidemia and other co-morbid disease such as hyper- or 
hypothyroidism. Thereafter, only 90 subjects were remained 
that fully fit above conditions. The study was carried out in 
Taleghani Pediatrics hospital in Gorgan (north of Iran); ap­
proved by the Research and Ethics committees of Golestan 
Fig. 1 Work flow diagram of the 
University of Medical Sciences (No. 2001). All participants 
were well informed by the authors and signed individually an 
informed consent form. All data obtained were kept confiden­
tial. No intervention was performed on the patients, and they 
paid no additional charge. 
All blood samples were obtained after an overnight 10– 
12 h of fasting. The FPG and triglyceride were measured by 
Prestige 24i fully automatic clinical chemistry analyzer (Ja­
pan). The plasma insulin level was determined using human 
insulin enzyme-linked immunosorbent assay kit. 
Agreement assessment 
As shown in Fig. 1, 26 patients were randomly selected and 
calculated their TyG index, Ln [fasting triglyceride (mg/dl) × 
fasting glucose (mg/dl)/2], and HOMA-IR, [fasting glucose 
(mg/dl) × insulin (mU/L)]/405, simultaneously. The agree­
ment between TyG and HOMA-IR were studied with the ex­
tension of limit of agreement (LOA) [17] which produced 
study N=200 Patients Surveyed in Taleghani 
Pediatrics hospital in Gorgan 
Select a random sample with size N=26 and
Exclusion criteria were checked. 110 patients 
collect their related data and calculate HOMA-
dropped and N=90 remained. 
IR and TyG indices for all of them. 
Checking the agreement between HOMA-IR 
TyG indices were calculated for 90 patients. and TyG with Bland-Altman plot and modeling 
it with limits of agreement(LOA) models. 
TyG indices were calculated for each patient 
in their next visits to the hospital. 
Paired sample-test were used to test the 
differences between baseline TyG and after 
two year TyG indices. 
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prediction limits between two indices with MethCamp pack­
age in R [18, 19]. 
Comparing two TyG 
Then, TyG index for whole 90 patients were calculated. Dur­
ing 2 years follow-up of these patients and in each visit to the 
Taleghiani hospital, their TyG indices were recorded. The 
paired t test was used for comparing TyG indices. The power 
of the test was conducted with PASS 11 [20]. 
Simulation study 
Monte Carlo simulations with 1000 replicates were conducted 
to figure out the possible range of TyG indexes based on these 
90 patients. For this purpose, the distributions of fasting tri­
glyceride and FPG in base line and after 2 years were fitted. 
The fitted distributions were used to simulate TyG index. All 
statistical analysis conducted with IBM SPSS version 22. 
Diagnosis of IR 
Two cutoff values including 4.515 and 4.68 were considered 
for IR detection. In support of the first threshold (e.g., 4.515), 
the reported sensitivity and specificity for IR detection was 70 
and 85 %, respectively, and for the second threshold (e.g., 
4.68), the reported sensitivity and specificity was 60 and 
95.5 %, respectively [9, 13]. The relations of TyG index with 
some proposed markers of IR in βTM including ferritin and 
AST were also investigated. 
Results 
The demographic characteristics of n=90 patients were shown in 
Table 1. The mean and standard deviation of participant’s age  
and height was 19.87±8.15 years and 146.77±28.16 cm simul­
taneously. The ratio of sex is very close for male and female with 
53.3 % male. The reported weight and ferritin were included the 
measured values at first visit and after 2 years later. Among the 
participants, 25.6%had done splenectomy. Most patients hadO+ 
(43.8 %) or A+ (22.5 %) blood group. The systolic and diastolic 
blood pressures were 101.68±18.00 and 65.15±10.90 mmHg, 
respectively. According to the number ofmissing values for these 
characteristics, only age, sex, height, splenectomy, and blood 
group were given good estimates. 
A random sample with size  n=26were chosen to assess the  
agreement between HOMA-IR and TyG indexes. Table 2 
were summarized the descriptive statistics of these two 
methods. The minimum value of HOMA-IR was 0.1999, 
but for TyG, it was 4.302, and the maximum value of 
HOMA-IR was 3.298, but for TyG, it was 5.272. Also, the 
median of these two methods were far from each other, 1.52 
Table 1 Demographic characteristics of N=90 patients 
N of missing N=90 patients 
Age (years)a 19.87±8.15 
Sex (% male) 53.3 % (n=48)  
Height (centimeter) 146.77±28.16 
Weight (kilogram) 
First visit 22 38.68±16.65 
Two year later visit 64 49.13±16.40 
Ferritin (ng/ml) 
First visit 40 7111.38±15422.15 
Two year later visit 20 4259.41±2630.893 
Splenectomy (% +) 25.6 % (n=23)  
Blood group (%) 1 
A+ 22.5 % (n=20)  
A− 6.7 % (n=6)  
AB 7.9 % (n=7)  
O+ 43.8 % (n=39)  
O− 1.1 % (n=1)  
B+ 11.2 % (n=10)  
B− 3.4 % (n=3)  
AB− 3.4 % (n=3)  
Blood pressure (mm Hg) 
Systolic 44 101.68±18.00 
Diastolic 44 65.15±10.90 
Data presented as unadjusted means with standard deviations or percent-
ages (n) 
a At baseline 
for HOMA-IR and 4.854 for TyG. Therefore, regular limit of 
agreement methods such as Bland-Altman plot were produced 
misleading result. Instead the extension to LOA by regression 
were used which were relaxed to some assumptions. Accord­
ing to Fig. 2, all dots are in the prediction limits except one 
which was an outlier. The agreement between HOMA-IR and 
TyG were assessed for this sample. 
A paired sample t test was conducted to compare TyG score 
between the first and the 2-year later visit. There was a signif­
icant difference in the TyG scores for the first visit (mean= 
4.610, SD=0.212) and 2-year later visit (mean=4.854, SD= 
0.204); t (89)=−14.244, P<0.001. The power of this test were 
calculated >0.99. Sex difference was not observed for TyG in 
both sessions. An increasing trend of TyG index with age was 
existed but it was not statistically significant. 
Table 2 Descriptive statistics of two methods of HOMA-IR and TyG 
based on a random sample with size 26 
Method Number Min Median Max 
HOMA-IR 26 0.199 1.520 3.298 
TyG 26 4.302 4.854 5.272 
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Fig. 2 Prediction limits between Prediction Limits 
two methods TyG and HOMA-IR 
HOMA 
Fig. 3 The first and the second 
TyG index for male and female 
patients 
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The distributions of fasting triglyceride and FPG were 
fitted to log-normal and normal distributions simultaneously. 
The Monte Carlo simulation with n= 1000 replicates were 
conducted using these distributions. The results for the first 
and the 2-year later visit were as follows. The mean, median, 
and standard deviation values of simulated study (first visit 
4.632, 4.613, and 0.226; 2-year later visit 4.850, 4.838, and 
0.201, respectively) had negligible difference with actual 
values (first visit 4.610, 4.604, and 0.212; 2-year later visit 
4.854, 4.829, and 0.204, respectively). But the standard errors 
of simulated data in the first and 2-year later visit (0.007 and 
0.006) were dramatically lower than actual values (0.022 and 
0.021). The minimum values of TyG in actual data were 4.08 
and 4.30, which in simulated data were 3.98 and 4.17 for the 
first and 2-year later visit, simultaneously. Also, the maximum 
values of TyG in actual data were 5.08 and 5.38, which in 
simulated data were 5.44 and 5.56 for the first and 2-year later 
visit, simultaneously. These results were expressed that TyG 
indexes can vary from 3.98 to 5.56. 
According to the value of FPG in the first and in the 2-year 
later visit, 14.4 % (14.6 % male, 14.3 % female) and 37.8 % 
(27.1 % male, 50 % female) had impaired fasting glucose 
level (100–125 mg/dl), respectively. The means and 95 % 
confidence intervals of the TyG indices are differentially 
shown for the male and female patients during 2 years interval 
in Fig. 3. Based on TyG.1, %34.4 (%25 of males and%45.2 of 
females) and based on TyG.2, %82.2 (83.3 % of males and 
81 % of females) of patients were detected as IR cases (e.g., 
had values greater than 4.68). The correlation of TyG index 
with ferritin (P= 0.018, R=0.282) and AST (P= 0.039, R= 
0.226) was considerable. 
Discussion 
We observed that the TyG index increased significantly in 
βTM patients in the 2 years interval. This index was used 
for the early detection of IR and offered as a screening tool 
for prediabetic state [9–11]. The gold standard test for IR is 
insulin clamp which is an invasive technique and needs well-
trained staff [21]. The HOMA-IR and QUICKI indices are 
well-known estimators for IR too. They are calculated from 
fasting plasma insulin and glucose level. Different HOMA-IR 
values were reported as normal in thalassemia major. In 2014, 
Li reported the IR in 71 Taiwanese patients with thalassemia 
major (32 male, 39 female; mean age±SD 21.7±6.3 years) 
and defined HOMA-IR <1.6 as normal [22]. In our study 
based on TyG.1 with considering 4.515 and 4.68 as IR cutoffs, 
67.8 and 34.4 % of patients had IR respectively. Also, based 
on TyG.2 with the same cut offs, 96.7 and 82.2 % of patients 
had IR, respectively. These findings were consistent with oth­
er reports about high prevalence of IR among βTM patients 
[23]. 
It is reported that iron overload in βTM is associated with 
IR. This overload is accounted as the main cause of diabetes in 
βTM [24]. In some studies, serum level of ferritin is presented 
as a risk factor for developing glucose tolerance abnormalities 
in βTM patients [25, 26]. 
The increased serum level of aminotransferases in βTM 
patients mainly attributes to iron overload and is also linked 
to IR in them [23]. A similar outline was observed in this study 
because the TyG.2 index had significant correlation with AST 
(P<0.05,  R=0.226).  
Both the IR and the deficiency of insulin are reported in 
βTM [27]. However, there are some controversies regarding 
the order of their occurrences or their causative role for differ­
ent glucose abnormalities in βTM [28–30]. Despite these dis­
agreements, the early detection of IR per se is a well-known 
recommendation [22]. There are different estimates about the 
prevalence of insulin resistance in thalassemia major. There 
are also different estimates about the prevalence of diabetes in 
βTM patients that ranges from less than 10 % to more than 
30 % [6, 31–33] at most; this variation might be due to eth­
nicity or genetic factors [34]. We did not enroll diabetics in 
this study, but our finding about the impaired fasting glucose 
in the first and second session was similar to other reports [34, 
35]. 
The prediction limits between TyG and HOMA-IR show 
good agreement. Our data also match with Monte Carlo sim­
ulation results and may suggest the application of TyG as an 
IR marker for βTM patients. The simplicity of TyG index has 
practical outcomes such as accessibility and less cost. These 
properties may be very important in low-income populations 
at risk for metabolic syndrome and diabetes as well as for 
offering it as screening test [12–14]. However, the age and 
sex dependent cutoff values for TyG are not well established 
and more studies need to do. 
Conclusion 
TyG index may be suggested as a helpful marker for revealing 
the insulin resistance in βTM patients especially when repeat­
ed in regular intervals. 
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